Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Variable cytoplasmic actin expression impacts the sensitivity of different dystrophin-deficient mdx skeletal muscles to eccentric contraction.

Lindsay A, Southern WM, McCourt PM, Larson AA, Hodges JS, Lowe DA, Ervasti JM.

FEBS J. 2019 Jul;286(13):2562-2576. doi: 10.1111/febs.14831. Epub 2019 Apr 11.

PMID:
30942954
2.

Distinct mechanical properties in homologous spectrin-like repeats of utrophin.

Rajaganapathy S, McCourt JL, Ghosal S, Lindsay A, McCourt PM, Lowe DA, Ervasti JM, Salapaka MV.

Sci Rep. 2019 Mar 26;9(1):5210. doi: 10.1038/s41598-019-41569-4.

3.

Corrigendum: Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Jun 1;28(11):1930. doi: 10.1093/hmg/ddz035. No abstract available.

4.

Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.

Lindsay A, Larson AA, Verma M, Ervasti JM, Lowe DA.

J Appl Physiol (1985). 2019 Feb 1;126(2):363-375. doi: 10.1152/japplphysiol.00948.2018. Epub 2018 Dec 20.

PMID:
30571283
5.

Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Apr 1;28(7):1117-1135. doi: 10.1093/hmg/ddy418. Erratum in: Hum Mol Genet. 2019 Jun 1;28(11):1930.

6.

Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle.

Olthoff JT, Lindsay A, Abo-Zahrah R, Baltgalvis KA, Patrinostro X, Belanto JJ, Yu DY, Perrin BJ, Garry DJ, Rodney GG, Lowe DA, Ervasti JM.

Nat Commun. 2018 Nov 30;9(1):5104. doi: 10.1038/s41467-018-07639-3.

7.

Dystrophinopathy-associated dysfunction of Krebs cycle metabolism.

Lindsay A, Chamberlain CM, Witthuhn BA, Lowe DA, Ervasti JM.

Hum Mol Genet. 2019 Mar 15;28(6):942-951. doi: 10.1093/hmg/ddy404.

PMID:
30476171
8.

Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.

Lindsay A, McCourt PM, Karachunski P, Lowe DA, Ervasti JM.

Free Radic Biol Med. 2018 Dec;129:364-371. doi: 10.1016/j.freeradbiomed.2018.10.404. Epub 2018 Oct 10.

PMID:
30312761
9.

Integrative effects of dystrophin loss on metabolic function of the mdx mouse.

Strakova J, Kamdar F, Kulhanek D, Razzoli M, Garry DJ, Ervasti JM, Bartolomucci A, Townsend D.

Sci Rep. 2018 Sep 11;8(1):13624. doi: 10.1038/s41598-018-31753-3.

10.

Essential nucleotide- and protein-dependent functions of Actb/β-actin.

Patrinostro X, Roy P, Lindsay A, Chamberlain CM, Sundby LJ, Starker CG, Voytas DF, Ervasti JM, Perrin BJ.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7973-7978. doi: 10.1073/pnas.1807895115. Epub 2018 Jul 16.

11.

Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins.

Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM.

Hum Mol Genet. 2018 Jun 12. doi: 10.1093/hmg/ddy209. [Epub ahead of print] No abstract available.

12.

Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.

Lindsay A, Schmiechen A, Chamberlain CM, Ervasti JM, Lowe DA.

Exp Physiol. 2018 Jul;103(7):995-1009. doi: 10.1113/EP087031.

13.

Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins.

Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM.

Hum Mol Genet. 2018 Jun 15;27(12):2090-2100. doi: 10.1093/hmg/ddy113. Erratum in: Hum Mol Genet. 2018 Jun 12;:.

14.

Impaired muscle relaxation and mitochondrial fission associated with genetic ablation of cytoplasmic actin isoforms.

O'Rourke AR, Lindsay A, Tarpey MD, Yuen S, McCourt P, Nelson DM, Perrin BJ, Thomas DD, Spangenburg EE, Lowe DA, Ervasti JM.

FEBS J. 2018 Feb;285(3):481-500. doi: 10.1111/febs.14367. Epub 2018 Jan 8.

15.

Mouse models of two missense mutations in actin-binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy.

McCourt JL, Talsness DM, Lindsay A, Arpke RW, Chatterton PD, Nelson DM, Chamberlain CM, Olthoff JT, Belanto JJ, McCourt PM, Kyba M, Lowe DA, Ervasti JM.

Hum Mol Genet. 2018 Feb 1;27(3):451-462. doi: 10.1093/hmg/ddx414.

16.

Independent variability of microtubule perturbations associated with dystrophinopathy.

Belanto JJ, Olthoff JT, Mader TL, Chamberlain CM, Nelson DM, McCourt PM, Talsness DM, Gundersen GG, Lowe DA, Ervasti JM.

Hum Mol Genet. 2016 Nov 15;25(22):4951-4961. doi: 10.1093/hmg/ddw318.

17.

Relative importance of βcyto- and γcyto-actin in primary mouse embryonic fibroblasts.

Patrinostro X, O'Rourke AR, Chamberlain CM, Moriarity BS, Perrin BJ, Ervasti JM.

Mol Biol Cell. 2017 Mar 15;28(6):771-782. doi: 10.1091/mbc.E16-07-0503. Epub 2017 Jan 11.

18.

Actin Is Crucial for All Kinetically Distinguishable Forms of Endocytosis at Synapses.

Wu XS, Lee SH, Sheng J, Zhang Z, Zhao WD, Wang D, Jin Y, Charnay P, Ervasti JM, Wu LG.

Neuron. 2016 Dec 7;92(5):1020-1035. doi: 10.1016/j.neuron.2016.10.014. Epub 2016 Nov 10.

19.

High Frequency Hearing Loss and Hyperactivity in DUX4 Transgenic Mice.

Dandapat A, Perrin BJ, Cabelka C, Razzoli M, Ervasti JM, Bartolomucci A, Lowe DA, Kyba M.

PLoS One. 2016 Mar 15;11(3):e0151467. doi: 10.1371/journal.pone.0151467. eCollection 2016.

20.

Pax3-induced expansion enables the genetic correction of dystrophic satellite cells.

Filareto A, Rinaldi F, Arpke RW, Darabi R, Belanto JJ, Toso EA, Miller AZ, Ervasti JM, McIvor RS, Kyba M, Perlingeiro RC.

Skelet Muscle. 2015 Oct 26;5:36. doi: 10.1186/s13395-015-0061-7. eCollection 2015.

21.

Disease-proportional proteasomal degradation of missense dystrophins.

Talsness DM, Belanto JJ, Ervasti JM.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12414-9. doi: 10.1073/pnas.1508755112. Epub 2015 Sep 21.

22.

In vitro stability of therapeutically relevant, internally truncated dystrophins.

McCourt JL, Rhett KK, Jaeger MA, Belanto JJ, Talsness DM, Ervasti JM.

Skelet Muscle. 2015 Apr 28;5:13. doi: 10.1186/s13395-015-0040-z. eCollection 2015.

23.

Length regulation of mechanosensitive stereocilia depends on very slow actin dynamics and filament-severing proteins.

Narayanan P, Chatterton P, Ikeda A, Ikeda S, Corey DP, Ervasti JM, Perrin BJ.

Nat Commun. 2015 Apr 21;6:6855. doi: 10.1038/ncomms7855.

24.

Creatine kinase B is necessary to limit myoblast fusion during myogenesis.

Simionescu-Bankston A, Pichavant C, Canner JP, Apponi LH, Wang Y, Steeds C, Olthoff JT, Belanto JJ, Ervasti JM, Pavlath GK.

Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C919-31. doi: 10.1152/ajpcell.00029.2015. Epub 2015 Mar 25.

25.

Microtubule binding distinguishes dystrophin from utrophin.

Belanto JJ, Mader TL, Eckhoff MD, Strandjord DM, Banks GB, Gardner MK, Lowe DA, Ervasti JM.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5723-8. doi: 10.1073/pnas.1323842111. Epub 2014 Mar 31.

26.

Postanesthetic death in a cat with myopathy.

Remmers G, Hayden DW, Jaeger MA, Ervasti JM, Valberg SJ.

Vet Pathol. 2015 Jan;52(1):186-8. doi: 10.1177/0300985814524797. Epub 2014 Feb 27.

PMID:
24577720
27.

The ZZ domain of dystrophin in DMD: making sense of missense mutations.

Vulin A, Wein N, Strandjord DM, Johnson EK, Findlay AR, Maiti B, Howard MT, Kaminoh YJ, Taylor LE, Simmons TR, Ray WC, Montanaro F, Ervasti JM, Flanigan KM.

Hum Mutat. 2014 Feb;35(2):257-64. doi: 10.1002/humu.22479. Epub 2013 Dec 2.

28.

β-Actin and fascin-2 cooperate to maintain stereocilia length.

Perrin BJ, Strandjord DM, Narayanan P, Henderson DM, Johnson KR, Ervasti JM.

J Neurosci. 2013 May 8;33(19):8114-21. doi: 10.1523/JNEUROSCI.0238-13.2013.

29.

An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells.

Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, Mayerhofer T, Chamberlain JS, Ervasti JM, McIvor RS, Kyba M, Perlingeiro RC.

Nat Commun. 2013;4:1549. doi: 10.1038/ncomms2550.

30.

Actin isoforms in neuronal development and function.

Cheever TR, Ervasti JM.

Int Rev Cell Mol Biol. 2013;301:157-213. doi: 10.1016/B978-0-12-407704-1.00004-X. Review.

PMID:
23317819
31.

Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Lin AY, Prochniewicz E, Henderson DM, Li B, Ervasti JM, Thomas DD.

J Mol Biol. 2012 Jun 29;420(1-2):87-98. doi: 10.1016/j.jmb.2012.04.005. Epub 2012 Apr 11.

32.

Restricted morphological and behavioral abnormalities following ablation of β-actin in the brain.

Cheever TR, Li B, Ervasti JM.

PLoS One. 2012;7(3):e32970. doi: 10.1371/journal.pone.0032970. Epub 2012 Mar 5.

33.

Multi-isotope imaging mass spectrometry reveals slow protein turnover in hair-cell stereocilia.

Zhang DS, Piazza V, Perrin BJ, Rzadzinska AK, Poczatek JC, Wang M, Prosser HM, Ervasti JM, Corey DP, Lechene CP.

Nature. 2012 Jan 15;481(7382):520-4. doi: 10.1038/nature10745.

34.

The carboxy-terminal third of dystrophin enhances actin binding activity.

Henderson DM, Lin AY, Thomas DD, Ervasti JM.

J Mol Biol. 2012 Feb 24;416(3):414-24. doi: 10.1016/j.jmb.2011.12.040. Epub 2011 Dec 28.

35.

Structural and functional properties of the actin gene family.

Bunnell TM, Ervasti JM.

Crit Rev Eukaryot Gene Expr. 2011;21(3):255-66. Review.

PMID:
22111713
36.

Transgenic overexpression of γ-cytoplasmic actin protects against eccentric contraction-induced force loss in mdx mice.

Baltgalvis KA, Jaeger MA, Fitzsimons DP, Thayer SA, Lowe DA, Ervasti JM.

Skelet Muscle. 2011 Oct 13;1(1):32. doi: 10.1186/2044-5040-1-32.

37.

β-Actin specifically controls cell growth, migration, and the G-actin pool.

Bunnell TM, Burbach BJ, Shimizu Y, Ervasti JM.

Mol Biol Cell. 2011 Nov;22(21):4047-58. doi: 10.1091/mbc.E11-06-0582. Epub 2011 Sep 7.

38.

TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice.

Call JA, Ervasti JM, Lowe DA.

J Appl Physiol (1985). 2011 Jul;111(1):200-5. doi: 10.1152/japplphysiol.00248.2011. Epub 2011 May 12.

39.

Internal deletion compromises the stability of dystrophin.

Henderson DM, Belanto JJ, Li B, Heun-Johnson H, Ervasti JM.

Hum Mol Genet. 2011 Aug 1;20(15):2955-63. doi: 10.1093/hmg/ddr199. Epub 2011 May 10.

40.

Axonal regeneration and neuronal function are preserved in motor neurons lacking ß-actin in vivo.

Cheever TR, Olson EA, Ervasti JM.

PLoS One. 2011 Mar 22;6(3):e17768. doi: 10.1371/journal.pone.0017768.

41.

Quadriceps myopathy caused by skeletal muscle-specific ablation of β(cyto)-actin.

Prins KW, Call JA, Lowe DA, Ervasti JM.

J Cell Sci. 2011 Mar 15;124(Pt 6):951-7. doi: 10.1242/jcs.079848. Epub 2011 Feb 15.

42.

β-actin and γ-actin are each dispensable for auditory hair cell development but required for Stereocilia maintenance.

Perrin BJ, Sonnemann KJ, Ervasti JM.

PLoS Genet. 2010 Oct 14;6(10):e1001158. doi: 10.1371/journal.pgen.1001158.

43.

The actin gene family: function follows isoform.

Perrin BJ, Ervasti JM.

Cytoskeleton (Hoboken). 2010 Oct;67(10):630-4. doi: 10.1002/cm.20475. Review.

44.

Delayed embryonic development and impaired cell growth and survival in Actg1 null mice.

Bunnell TM, Ervasti JM.

Cytoskeleton (Hoboken). 2010 Sep;67(9):564-72. doi: 10.1002/cm.20467.

45.

Site mapping and characterization of O-glycan structures on alpha-dystroglycan isolated from rabbit skeletal muscle.

Stalnaker SH, Hashmi S, Lim JM, Aoki K, Porterfield M, Gutierrez-Sanchez G, Wheeler J, Ervasti JM, Bergmann C, Tiemeyer M, Wells L.

J Biol Chem. 2010 Aug 6;285(32):24882-91. doi: 10.1074/jbc.M110.126474. Epub 2010 May 27.

46.

Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation.

Henderson DM, Lee A, Ervasti JM.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9632-7. doi: 10.1073/pnas.1001517107. Epub 2010 May 10.

47.

Dystrophin is a microtubule-associated protein.

Prins KW, Humston JL, Mehta A, Tate V, Ralston E, Ervasti JM.

J Cell Biol. 2009 Aug 10;186(3):363-9. doi: 10.1083/jcb.200905048. Epub 2009 Aug 3.

48.

Gamma-actin is required for cytoskeletal maintenance but not development.

Belyantseva IA, Perrin BJ, Sonnemann KJ, Zhu M, Stepanyan R, McGee J, Frolenkov GI, Walsh EJ, Friderici KH, Friedman TB, Ervasti JM.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9703-8. doi: 10.1073/pnas.0900221106. Epub 2009 Jun 3.

49.

Functional substitution by TAT-utrophin in dystrophin-deficient mice.

Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, Ervasti JM.

PLoS Med. 2009 May 26;6(5):e1000083. doi: 10.1371/journal.pmed.1000083. Epub 2009 May 26.

50.

Dystrophin and utrophin have distinct effects on the structural dynamics of actin.

Prochniewicz E, Henderson D, Ervasti JM, Thomas DD.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7822-7. doi: 10.1073/pnas.0812007106. Epub 2009 Apr 30.

Supplemental Content

Loading ...
Support Center